Long-term safety and effect of GW906 injection in adults with high blood pressure
Tests GW906 injection over a longer time in adults with essential hypertension.
Plain-language title generated from the registry record
Registry title: An Extension Trial of GW 906 in Participants With Essential Hypertension
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Shanghai Jiao Tong University School of Medicine - Ruijin HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Trial code
- NCT07879755
- Record updated
- 19 October 2026
- Original description
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906Read full original descriptionShow less
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of GW906 (SAL0132) Injection in Patients With Essential Hypertension
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906
Inclusion: Completed study treatment and the study in accordance with the protocol for GW906 injection; Willing to participate in the study and provide written informed consent.
Exclusion: Orthostatic hypotension accompanied by hypotension-related symptoms was observed in a prior study of GW906 injection; Secondary hypertension; History of any cardiovascular event within 6 months; Patients with active malignancy or a history of malignancy; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; International normalized ratio (INR) > 2.0; Serum potassium > 5.0 mmol/L or < 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2.